NCT06259331View on ClinicalTrials.gov

Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women

PHASE4CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

September 20, 2023

Study Completion Date

September 20, 2023

Conditions

Healthy Lactating Women

Interventions

DRUG

SPN-812 (600mg, QD)

Viloxazine ER

Trial Locations (1)

89113

PPD Phase I Clinic, Las Vegas

All Listed Sponsors

lead

Supernus Pharmaceuticals, Inc.

INDUSTRY